References
- Rosenfeld PJ , BrownDM, HeierJS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 , 1419–1431 (2006).
- Brown DM , KaiserPK, MichelsM et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355 , 1432–1444 (2006).
- Agosta E , LazzeriS, OrlandiP et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics 13 , 1037–1053 (2012).
- Lazzeri S , FigusM, OrlandiP et al. VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics14 , 623–630 (2013).
- Hagstrom SA , YingGS, PauerGJ et al. Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT). Ophthalmology 120 , 593–599 (2013).
- Chang W , NohDH, SagongM et al. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population. Mol. Vision 19 , 702–709 (2013).
- Abedi F , WickremasingheS, RichardsonAJ et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 120 , 115–121 (2013).
- Boltz A , RuißM, JonasJB et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. Ophthalmology 119 , 1615–1620 (2012).
- Chen H , YuKD, XuGZ. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis. PLoS ONE7 , e42464 (2012).
- Wang VM , RosenRB, MeyerleCB et al. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. Mol. Vision 18 , 2578–2585 (2012).
- Yamashiro K , TomitaK, TsujikawaA et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am. J. Ophthalmol. 154 , 125–136 (2012).
- Smailhodzic D , MuetherPS, ChenJ et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 119 , 2304–2311 (2012).
- Orlin A , HadleyD, ChangW et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 32 , 4–9 (2012).
- Funk M , KarlD, GeorgopoulosM et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116 , 2393–2399 (2009).
- Tong JP , ChanWM, LiuDT et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am. J. Ophthalmol. 141 , 456–462 (2006).
- Lai TY , LiuDT, ChanKP, LukFO, PangCP, LamDS. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial. Retina29 , 1218–1226 (2009).
- Lin J , WanL, TsaiYY et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am. J. Ophthalmol. 145 , 1045–1051 (2008).
- Brown DM , ChenE, MarianiA et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration – primary end point. Ophthalmology 120 , 349–354 (2013).
- Bocci G , LoupakisF. The possible role of chemotherapy in antiangiogenic drug resistance. Med. Hypotheses78 , 646–648 (2012).
- Leveziel N , PelatT, WatierH et al. Detection of anti-ranibizumab antibodies among exudative AMD patients. Association for Research in Vision and Ophthalmology (ARVO) Meeting. Seattle, WA, USA, 5–9 May 2013 (Abstract 3170).